Literature DB >> 31587361

In silico design and molecular basis for the selectivity of Olinone toward the first over the second bromodomain of BRD4.

Yoel Rodríguez1,2, Guillermo Gerona-Navarro3,4, Roman Osman2, Ming-Ming Zhou2.   

Abstract

Bromodomains (BrDs), a conserved structural module in chromatin-associated proteins, are well known for recognizing ε-N-acetyl lysine residues on histones. One of the most relevant BrDs is BRD4, a tandem BrD containing protein (BrD1 and BrD2) that plays a critical role in numerous diseases including cancer. Growing evidence shows that the two BrDs of BRD4 have different biological functions; hence selective ligands that can be used to study their functions are of great interest. Here, as a follow-up of our previous work, we first provide a detailed characterization study of the in silico rational design of Olinone as part of a series of five tetrahydropyrido indole-based compounds as BRD4 BrD1 inhibitors. Additionally, we investigated the molecular basis for Olinone's selective recognition by BrD1 over BrD2. Molecular dynamics simulations, free energy calculations, and conformational analyses of the apo-BRD4-BrD1|2 and BRD4-BrD1|2/Olinone complexes showed that Olinone's selectivity is facilitated by five key residues: Leu92 in BrD1|385 in BrD2 of ZA loop, Asn140|433, Asp144|His437 and Asp145|Glu438 of BC loop, and Ile146|Val49 of helix C. Furthermore, the difference in hydrogen bonds number and in mobility of the ZA and BC loops of the acetyl-lysine binding site between BRD4 BrD1/Olinone and BrD2/Olinone complexes also contribute to the difference in Olinone's binding affinity and selectivity toward BrD1 over BrD2. Altogether, our computer-aided molecular design techniques can effectively guide the development of small-molecule BRD4 BrD1 inhibitors, explain their selectivity origin, and further open doors to the design of new therapeutically improved derivatives.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  bromodomains; conformational analysis; free energy calculations; molecular dynamics simulations; selectivity; structure-based drug design

Mesh:

Substances:

Year:  2019        PMID: 31587361      PMCID: PMC6982606          DOI: 10.1002/prot.25818

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  50 in total

Review 1.  Epigenetic protein families: a new frontier for drug discovery.

Authors:  Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira
Journal:  Nat Rev Drug Discov       Date:  2012-04-13       Impact factor: 84.694

2.  Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition.

Authors:  Guangtao Zhang; Ruijie Liu; Yifei Zhong; Alexander N Plotnikov; Weijia Zhang; Lei Zeng; Elena Rusinova; Guillermo Gerona-Nevarro; Natasha Moshkina; Jennifer Joshua; Peter Y Chuang; Michael Ohlmeyer; John Cijiang He; Ming-Ming Zhou
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

3.  Ligand configurational entropy and protein binding.

Authors:  Chia-en A Chang; Wei Chen; Michael K Gilson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-22       Impact factor: 11.205

4.  BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice.

Authors:  Kalung Cheung; Geming Lu; Rajal Sharma; Adam Vincek; Ruihua Zhang; Alexander N Plotnikov; Fan Zhang; Qiang Zhang; Ying Ju; Yuan Hu; Li Zhao; Xinye Han; Jamel Meslamani; Feihong Xu; Anbalagan Jaganathan; Tong Shen; Hongfa Zhu; Elena Rusinova; Lei Zeng; Jiachi Zhou; Jianjun Yang; Liang Peng; Michael Ohlmeyer; Martin J Walsh; David Y Zhang; Huabao Xiong; Ming-Ming Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-06       Impact factor: 11.205

Review 5.  Fragment-based in silico screening of bromodomain ligands.

Authors:  Dimitrios Spiliotopoulos; Amedeo Caflisch
Journal:  Drug Discov Today Technol       Date:  2016-07-21

6.  Suppression of inflammation by a synthetic histone mimic.

Authors:  Edwige Nicodeme; Kate L Jeffrey; Uwe Schaefer; Soren Beinke; Scott Dewell; Chun-Wa Chung; Rohit Chandwani; Ivan Marazzi; Paul Wilson; Hervé Coste; Julia White; Jorge Kirilovsky; Charles M Rice; Jose M Lora; Rab K Prinjha; Kevin Lee; Alexander Tarakhovsky
Journal:  Nature       Date:  2010-11-10       Impact factor: 49.962

7.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB.

Authors:  James A Maier; Carmenza Martinez; Koushik Kasavajhala; Lauren Wickstrom; Kevin E Hauser; Carlos Simmerling
Journal:  J Chem Theory Comput       Date:  2015-07-23       Impact factor: 6.006

Review 8.  The role of human bromodomains in chromatin biology and gene transcription.

Authors:  Roberto Sanchez; Ming-Ming Zhou
Journal:  Curr Opin Drug Discov Devel       Date:  2009-09

9.  Histone recognition and large-scale structural analysis of the human bromodomain family.

Authors:  Panagis Filippakopoulos; Sarah Picaud; Maria Mangos; Tracy Keates; Jean-Philippe Lambert; Dalia Barsyte-Lovejoy; Ildiko Felletar; Rudolf Volkmer; Susanne Müller; Tony Pawson; Anne-Claude Gingras; Cheryl H Arrowsmith; Stefan Knapp
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

Review 10.  Drug Discovery Targeting Bromodomain-Containing Protein 4.

Authors:  Zhiqing Liu; Pingyuan Wang; Haiying Chen; Eric A Wold; Bing Tian; Allan R Brasier; Jia Zhou
Journal:  J Med Chem       Date:  2017-03-02       Impact factor: 7.446

View more
  2 in total

1.  Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development.

Authors:  Pan Tang; Jifa Zhang; Jie Liu; Cheng-Ming Chiang; Liang Ouyang
Journal:  J Med Chem       Date:  2021-02-22       Impact factor: 7.446

2.  Binding selectivity of inhibitors toward the first over the second bromodomain of BRD4: theoretical insights from free energy calculations and multiple short molecular dynamics simulations.

Authors:  Yan Wang; Shiliang Wu; Lifei Wang; Zhiyong Yang; Juan Zhao; Lulu Zhang
Journal:  RSC Adv       Date:  2020-12-24       Impact factor: 3.361

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.